Holen Sie sich die Stockscreener-App
11.33
1.39%
-0.16
Handel nachbörslich:
11.33
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
HC Wainwright Issues Optimistic Estimate for CBIO Earnings - MarketBeat
GLYC SEC FilingsGlycomimetics 10-K, 10-Q, 8-K Forms - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given New $22.00 Price Target at HC Wainwright - Defense World
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares after $185M placement - Stock Titan
CBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 - Investing.com Nigeria
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stifel cuts Crescent Biopharma stock price target on equity financing - Investing.com South Africa
Stifel cuts Crescent Biopharma stock price target on equity financing By Investing.com - Investing.com Canada
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-00 - Bitget
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ... - Bluefield Daily Telegraph
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Crescent Biopharma: Fourth Quarter Financial Results Overview - Bitget
Crescent Biopharma to Present at March Investor Conferences - Bitget
Cancer-focused biotech Crescent Biopharma plans March investor talks in Boston and Miami - Stock Titan
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - ADVFN
Crescent Biopharma announces grants of inducement awards - TipRanks
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Crescent Biopharma doses first patient in ASCEND cancer trial - Investing.com Nigeria
Should I Buy CBIO? CBIO 2026 AnalysisIntellectia AI™ - Intellectia AI
Crescent Biopharma announces first patient dosed in Ascend Phase 1/2 clinical trial of CR-001 - marketscreener.com
Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001 - TradingView
Crescent Biopharma Doses First Patient in ASCEND Trial of Solid Tumor Treatment - marketscreener.com
Crescent Biopharma doses first patient in ASCEND cancer trial By Investing.com - Investing.com Canada
Experimental cancer antibody CR-001 enters global trial in advanced solid tumors - Stock Titan
Mineurs de cuivre, Fresh Del Monte Produce, Crescent Biopharma - TradingView
Will Crescent Biopharma Inc. (GKO0) stock remain on Wall Street radarWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Is Crescent Biopharma Inc. (GKO0) stock in buy zone after pullback2025 Technical Patterns & Weekly High Return Forecasts - mfd.ru
CBIO: Global oncology pipeline advances with CR-001 and ADCs, backed by strong funding and partnerships - TradingView
FMR LLC's Strategic Acquisition of Crescent Biopharma Inc Shares - GuruFocus
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Clinical-stage biotech Crescent Biopharma joins Guggenheim summit Feb. 12 - Stock Titan
Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92 - Nasdaq
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded to "Strong-Buy" at Piper Sandler - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded at Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating - MarketBeat
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $35 - 富途资讯
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage - TipRanks
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):